1515
Xspray Pharma publishes Interim Report Q3, January – September 2020

”Xspray Pharma is in an eventful phase with several crucial milestones within reach. After completing bioequivalence studies, intensive work is being done on the preparations for the Company's first ANDA application and finding the right partner for HyNap-Dasa”. Per Andersson, CEO Xspray Pharma AB (publ)

Significant events during the third quarter, 2020

  • In August, a term sheet for a new manufacturing facility in Malta, with Pharmacare Premium Ltd, was signed.
  • In August, the preliminary results of the first study for HyNap-Dasa were announced. The study did not fulfil statistical bioequivalence requirements due to high variability in pharmacokinetic parameters for the reference product Sprycel®. A few subjects had very low absorption from Sprycel® which was not observed for HyNap-Dasa.
  • In August, the company strengthened its IP rights by receiving a Notice of Allowance from the US Patent Office regarding its patent application for tablets containing dasatinib propylene glycol solvate (dasatinib PG).
  • In August, it was announced that the CEO Per Andersson and other warrant holders have chosen to make full use of the opportunity to subscribe for shares in Xspray by fully exercising their respective number of warrants in the warrant program LTIP 2017/2020.
  • In August, six months data from the company's stability study with commercially manufactured HyNap-Dasa tablets were published. Data from the study demonstrates that the tablets comply with the specifications and that they can be used in an upcoming ANDA filing.
  • In September, the Chairman of the Board, Michael Wolff Jensen, announced that he will not be available for re-election at the 2021 Annual General Meeting.
  • In September, the preliminary results from the second out of two bioequivalence studies in healthy volunteers with HyNap-Dasa, were announced. The study fulfilled statistical and formal bioequivalence requirements for HyNap-Dasa compared to the reference product Sprycel®. The study was conducted in healthy volunteers under fed conditions.

Significant events after the end of the reporting period

  • In October, a directed new issue of shares was made at a subscription price of SEK 142.50 per share. The issue raised approximately SEK 265 million before transaction costs and increased the number of shares by 1,861,291, from 17,031,213 to 18,892,504.
  • In October, the composition of the Nomination Committee for the 2021 Annual General Meeting was announced.

Group, July - September 2020

  • Net sales amounted to SEK 0 thousand (0)
  • Earnings before tax amounted to SEK -11,560 thousand (-9,921)
  • Earnings per share before dilution amounted to SEK 0.69 (-0.62)
  • Cash flow from operating activities amounted to SEK -12,764 thousand (-8,747)
  • Cash flow from investing activities amounted to SEK -19,868 thousand (-22,898)

Group, January - September 2020

  • Net sales amounted to SEK 0 thousand (0)
  • Earnings before tax amounted to SEK -37,438 thousand (-27,033)
  • Earnings per share before dilution amounted to SEK -2.23 thousand (-1.79)
  • Cash flow from operating activities amounted to SEK -36,076 thousand (-22,692)
  • Cash flow from investing activities amounted to SEK -68,901 thousand (-67,846)
  • Cash and cash equivalents and current investments at the end of the period totalled SEK 116,622 thousand (130,657)

Amounts in brackets refer to the corresponding period for the previous year.

The report is available on the company’s website: http://xspraypharma.com/en/investors/financial-reports/

Source: MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till di.se med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Dagens industri som e-tidning redan kvällen innan

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr

Prenumerera

Redan prenumerant?